Ongoing Clinical Studies in Bladder Cancer

Cretostimogene grenadenorepvec (CG0070) is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and Phase 3 studies in the U.S. in BCG unresponsive NMIBC and MIBC. Two studies are actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.

Trial Title	Trial Number	Stage	Status	Publication
BOND-002 Safety and Efficacy	NCT02365818	Phase 2, US only	Completed	Phase 2 publication interim results
BOND-003 Phase 3	NCT04452591	Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)	Recruiting	Phase 2 publication interim results
CORE-001 Phase 2, CG0070 Combined With Pembrolizumab	NCT04387461	Phase 2, Global (US, South Korea)	Active, Not Recruiting	Phase 2 interim data (ASCO 2022)
CORE-002 Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC	NCT04610671	Phase 1b/2, US Only	Recruiting	Phase 1b/2 interim data (ASCO 2022):

Patients and Urologists interested in participating should contact:

JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.